$HOMB

HOME BANCSHARES INC

6
4
1

No SEC Form 4 filings for $HOMB in the last 30 days.

See all $HOMB insider activity →
Low

iShares Russell 2000 (IWM) Buys $3.6 Million More MiniMed on Oct. 20

iShares Russell 2000 (IWM) rebalanced its portfolio on October 20, with $153.2M in gross activity. It bought $3.6M in MiniMed (MMED), $1.2M in Jackson Financial (JXN), and $0.4M in Axos Financial (AX). It sold $5.5M in Radian Group (RDN), $4.8M in Home BancShares (HOMB), and $4.5M in Essent Group (ESNT).

A 23-cent dividend will be Home BancShares' 82nd straight quarterly payment

Home BancShares (NYSE: HOMB) increased its stock repurchase program by 6.55 million shares, bringing the total to 20 million. The company also declared a quarterly cash dividend of $0.23 per share, marking its 82nd consecutive quarterly payment. According to the company, strong earnings and capital position support these actions.

Piper Sandler maintains Neutral rating on Home Bancorp, $64 price target

Piper Sandler kept a Neutral rating on Home Bancorp (HOMB) with a $64 price target, suggesting a 7.6% upside. The bank's non-performing assets rose to 1.92%, raising credit quality concerns, while rising funding costs may limit profitability gains. The analyst note cites these factors for the cautious outlook.

HOMB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 11 news stories mentioning HOMB (HOME BANCSHARES INC). Coverage has skewed bullish: 6 bullish, 4 neutral, and 1 bearish.

Recent HOMB coverage spans earnings, financial news and corporate actions.

What's driving HOMB

AlphAI scores every news story that mentions HOMB with an AI model for sentiment and relevance, and aggregates insider trades from HOME BANCSHARES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HOMB

Score

HOMB Q3 Deep Dive: Margin Expansion and Capital Returns Drive Performance

HOMB reported Q3 performance driven by margin expansion and capital returns. Management expects continued net interest income growth due to variable rate loans and maturing fixed-rate loans. Loan growth is anticipated to improve, though competitive pressures remain. Credit quality and cost discipline are expected to support profitability. The stock is trading at $29.42, up from $28.29 pre-earnings.

$HOMBMed

Piper Sandler lowers Home Bancshares price target to $34 on growth

Piper Sandler cut its price target on Home Bancshares (HOMB) to $34 from $36, citing Q3 2026 results that beat EPS estimates but showed loan and deposit declines. The firm adjusted EPS estimates for 2026-2028, highlighting improved net interest margin and share repurchases. HOMB reported record Q3 earnings of $129.1M ($0.65 EPS), beating estimates, but revenue missed expectations. Analysts focus on strong profitability and capital levels.

$HOMBLow

Cantor Fitzgerald keeps Neutral on Home Bancshares stock at $31

Cantor Fitzgerald kept its Neutral rating on Home Bancshares (HOMB) with a $31 price target. The stock trades at $28.29, with a market cap of $5.66B. Q3 2026 earnings were mixed, with solid expense control but misses on net interest income and balance sheet trends. HOMB reported Q2 earnings and revenue above expectations, with record profitability and benefits from its acquisition. Analysts maintained Hold ratings with adjusted earnings estimates.

$HOMBMed

Home BancShares Reports Record Third Quarter Net Income, Bringing the Company Closer to a Half-Billion-Dollar Year

HOME BANCSHARES INC (HOMB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 For Immediate Release: October 14, 2026 Home BancShares Reports Record Third Quarter Net Income, Bringing the Company Closer to a Half-Billion-Dollar Year Conway, AR – Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, re

Related tickers